A technological breakthrough in the form of a SAW-DM32 fully automatic methylated nucleic acid extraction and purification instrument, independently developed by Jiangsu Bioperfectus Technologies, located in Taizhou city in East China's Jiangsu province, recently got the green light to be marketed.
The occurrence and development of tumors are closely related to abnormal DNA methylation.
As a promising biomarker, DNA methylation can be used for early screening, auxiliary diagnosis and recurrence monitoring of colorectal cancer, breast cancer, liver cancer and other tumors.
An exterior view of the premises of Jiangsu Bioperfectus Technologies. [Photo/WeChat account: weigg6666]
The new product is designed to be used in conjunction with a nucleic acid extraction kit and a methylation detection sample pretreatment kit, with a detection time only half that of traditional manual operations and with much higher accuracy.
The product can be used for clinical in vitro testing, suitable for various sample types such as cells, tissues and secretions.
With its automation performance, the product is expected to free up laboratory manpower, ensure the reliability and consistency of methylation pretreatment results, boost precision medicine and help laboratories open a new chapter in efficient, accurate and convenient methylation detection.